CFO’s Quiet 10b5‑1 Buy Signals Confidence in NEONC’s Oncology Pipeline and Capital‑Structure Overhaul
NeOnc CFO buys 5,000 shares at $3.36, signaling long‑term confidence amid a weak oncology market and promising Phase 2a data for NEO100.
3 minutes to read



